Rabbit Polyclonal COL8A2 Antibody

COL8A2 antibodies target the alpha-2 chain of collagen type VIII, a short-chain collagen primarily found in basement membranes and extracellular matrices. Encoded by the COL8A2 gene, this protein contributes to tissue structure and cellular adhesion. COL8A2 is notably expressed in vascular endothelial cells, the eye (particularly the corneal endothelium), and certain epithelial tissues. Research on COL8A2 antibodies has been driven by its association with Fuchs' endothelial corneal dystrophy (FECD), a genetic disorder causing corneal degeneration. Specific mutations in COL8A2. such as the L450W variant, are linked to early-onset FECD, making these antibodies valuable for studying disease mechanisms. Additionally, COL8A2 is implicated in angiogenesis and tumor microenvironment regulation, with studies suggesting its role in modulating blood vessel stability in cancers. Antibodies against COL8A2 are used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to localize and quantify its expression in tissues or cell cultures. They also aid in exploring COL8A2's interactions with signaling molecules involved in cell proliferation and matrix remodeling. While most applications remain research-focused, potential clinical uses include diagnostic tools for corneal dystrophies or biomarkers for vascular abnormalities. However, standardization of antibody specificity and validation across species and sample types remains a challenge in translating these findings into therapeutic or diagnostic advancements.